Andrey Soares
@SoaresAndrey
Followers
3K
Following
7K
Media
293
Statuses
5K
Scientific Committee Member LACOG - GU | Medical Oncologist at Hospital Albert Einstein | Owner and founder BIO | Following or RT does not mean endorsement
São Paulo, Brasil
Joined July 2009
@aron_project is more than an amazing collaborative research working group. It is a family. Thanks for this incredible journey. @MatteoSantoniMD @fmassari79 @drenriquegrande @JaviMolinaC @SoaresAndrey @vmollica7
0
3
12
Amazing team @aron_project
The soul of Oncology, the spirit of science: the @aron_project. Thanks @myesmo for allowing us to meet at #ESMO25 Not easy to see a group with more scientific production in the field of GU. @OncoAlert @fsabino_onco @SoaresAndrey @fmassari79 @MatteoSantoniMD @raymanneh
0
0
0
#ESMO25 | Standing room only at the 2nd International ARON Meeting! Don't miss the special issue of OncoInfo from Berlin, entirely dedicated to the topic of RWE in #genitourinarytumors, coming out in a few days. Stay tuned! 📡 @drenriquegrande @SoaresAndrey @fmassari79
0
4
4
Important data in patients with #mCRPC treated in the Brazilian Public Health System (#SUS) showing that Brazil loses money with non-life prolonging therapies, and with a better management more patients could increase the access to better drugs #ESMO25
Don’t miss to take a look in our poster at #ESMO25 . Evaluation of the types of systemic treatments as well as the associated costs in >30k mCRPC patients in the Brazilian public health system. @myESMO @SoaresAndrey @APCCC_Lugano @Silke_Gillessen
0
0
2
@tompowles1 @Annals_Oncology @JoshMeeks I would say they are all « clinically » non significant. The NNT is super high close to 20 with significant added cost and toxicity
0
3
16
5% EFS benefit is enough when we are adding systemic toxicity and costs over an almost ideal BCG maintenance (24 months)? #ESMO25
ALBAN #ESMO25 (atezolizumab/BCG vs BCG in MIBC) @Annals_Oncology did not ⬆️ EFS (HR0.97) unlike sasalimab & durvalumab in a similar setting. The drugs seem similar in metastatic UC so was it trial design making it different from other ICIs? EFS was defined differently.
0
0
0
0
9
16
Módulo Tumores GU @SMEOMX Cáncer de riñón, vejiga, prostata, testículo y pene. 🇧🇷🇦🇷🇲🇽🇺🇸 🟢tx nuevo x renal y vejiga 🔵Radioterapia, recaída Bioquímica 🟠Radioligsndos, iPARPs & hormono 🔴 Novedas Ca de pene IO
1
8
29
Thks to @SMEOMX 43 Congress!! GU module with strong nuclear medicine participation. #theranostic needs nuclear medicine as part of MDT discussion. Selection criteria, imaging response assessment and more. @BourlonMaite @SoaresAndrey @urologohector @UroTeragLATAM @RodRogSan
3
4
14
@BourlonMaite @SoaresAndrey @SMEOMX @TresUramigas @LACOG_group @OncoAlert @Uromigos @RodRogSan @brian_rini @grivas @UroTeragLATAM @INCMNSZ_Uronco @oncodaily @fsabino_onco @urologohector @DrFRodriguezCov Excelente coordinación del modulo GU en @SMEOMX a cargo de @BourlonMaite
0
3
10
En @SMEOMX con @UroTeragLATAM
@incanMX @incmnszmx Hablando de #cancerprostata y radiofarmscos Lu177-PSMA 🟣Beneficio en SG en mCRPC 🟠Multidisciplina necesaria 🌍 🟢Manejo de toxicidades 🦀👨🏻⚕️🥂Mejorando desenlaces
1
9
26
Magnificent talk from @SoaresAndrey at @SMEOMX #smeo2025 @TresUramigas @LACOG_group @OncoAlert @Uromigos 🇲🇽🇧🇷 1st line mHSPC duplet vs triplet 🟣De novo vs recurrent 🟢Value of PSMA-PET 🟠Which is the Best ARPi 🔴Drug interactions & side effects 🔵 iPAPs new kid in the block
0
0
1
A prognostic score for mUC patients treated with immunotherapy. Just out at @MetastasisRS Journal. Congrats @MatteoSantoniMD @fmassari79 @SoaresAndrey @DrYukselUrun @aron_project
https://t.co/7czAzSJXbx
2
7
12
Another important masterpiece of @aron_project . @MatteoSantoniMD @SoaresAndrey @BourlonMaite @DrYukselUrun
177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study Out now on EJC our last research by @aron_project
@oncodaily @OncoAlert
2
4
14
177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study https://t.co/iuNFwRCDQg In this large real-world study(n=568), patients with metastatic castration-resistant #ProstateCancer treated with
2
24
45
Renal Registry (LACOG 1120) reveals major disparities in kidney cancer care in Brazil: 5-yr OS is 79.6% (private) vs. 42% (public). Patients in the public system face later diagnoses, less access to novel therapies & worse outcomes. #ASCO25 #LACOG @ascocancer
1
5
11
Analysis from PEACE-3 shows that addition of radium-223 to enzalutamide improves PSA RR and ALP response in #mCRPC, confirming the efficacy of therapy. #ASCO25 @hosp_einstein
PSA and alkaline phosphatase changes in the EORTC-1333 #PEACE3 study evaluating the addition of six cycles of radium 223 in #mCRPC starting enzalutamide. Presentation by @SoaresAndrey @habblethiae. #ASCO25 written coverage by @zklaassen_md @GACancerCenter >
0
1
3
Dear Colleague, Join the Prostate Cancer Care Disparity Analysis Project (ProGAP) (NCT06612034) by taking our quick 6–8 minute survey on global disparities in prostate cancer treatment. Your input is vital in shaping better care. Thank you! Link👇👇👇 https://t.co/AI8axX4hKT
5
26
57
Important data confirming the activity and superiority of the combination versus enza monotherapy. #ASCO25
In PEACE-3 (EORTC 1333), the addition of 6 cycles of Ra223 to enzalutamide improves PSA response time and rates (≥90%), ALP reduction time (≥30%), and ALP normalization at 6 and 12 months. @EORTC @Silke_Gillessen @SoaresAndrey @GETUG_Unicancer @cancertrials_ie @sogug1
0
0
1
What a treat to meet @SoaresAndrey & #DiogoBuganoMD at the @hosp_einstein booth at #ASCO25. Have gotten to know so many phenomenal folks from this institution through our fellowship exchange; grateful to @mzugman for joining us at @cityofhope for an extended time period!
1
6
22